haematology
Blood cancers

Low relapse risk for young people with Hodgkin lymphoma

Young patients with classic Hodgkin lymphoma (cHL) have a low risk of relapse with current treatments and may not need intensive follow up if they achieve event-free survival of two years, according to a ‘real world’ study from Scandinavia. Analysis of a cohort of 2,582 Nordic patients with cHL diagnosed at ages 18 to 49 ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic